共 50 条
- [1] DEVELOPMENT OF MINIMAL RESIDUE DISEASE (MRD) ANALYSIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) BY NEXT GENERATION SEQUENCING (NGS)HAEMATOLOGICA, 2013, 98 : 1 - 1Williamson, H.Hancock, J.Moppett, J.Roberts, E.
- [2] Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)BLOOD, 2007, 110 (11) : 427A - 427AMoorman, Anthony V.Richards, Sue M.Hanock, Jerry P.Mitchell, Chris D.Vora, Ajay J.Harrison, Christine J.Goulden, Nick J.
- [3] Detection and quantitative monitoring of minimal residual disease (MRD) in acute lymphoblastic leukaemia (ALL) patients.BRITISH JOURNAL OF CANCER, 2002, 86 : S40 - S40Quinn, FCrampe, MBrowne, PO'Marcaigh, AStallings, RMcCann, SRSmith, OPO'Meara, ABreathnach, FLawler, M
- [4] The value of minimal residual disease (MRD) analysis in acute lymphoblastic leukaemia (ALL) for the prediction of relapse after BMT.BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 43 - 43Knechtli, CGoulden, NGarland, RHancock, JRowbottom, ASteward, CPotter, MOakhill, A
- [5] Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for allBRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (05) : 888 - 892Kuiper, Roland P.Hoogeveen, Patricia G.Bladergroen, Renovan Dijk, FreerkSonneveld, Edwinvan Leeuwen, Frank N.Boer, JudithSergeeva, IrinaFeitsma, Harmaden Boer, Monique L.van der Velden, Vincent H. J.
- [6] Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in TLymphoblastic Leukemia (T-ALL)BLOOD, 2023, 142Roy, NtashaMao, ZhengweiXu, ChangTeachey, David T.Chen, ZhiguoDevidas, MeenakshiChen, XueyanRaetz, Elizabeth A.Loh, Mignon L.Hunger, Stephen P.Wood, Brent L.
- [7] Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaBlood Cancer Journal, 10Alejandro MedinaNoemi PuigJuan Flores-MonteroCristina JimenezM.-Eugenia SarasqueteMaría Garcia-AlvarezIsabel Prieto-CondeCarmen ChillonMiguel AlcocebaNorma C. GutierrezAlbert OriolLaura RosinolJoan BladèMercedes GironellaMiguel T. HernandezVeronica Gonzalez-CalleMaria-Teresa CedenaBruno PaivaJesus F. San-MiguelJuan-Jose LahuertaMaria-Victoria MateosJoaquin Martinez-LopezAlberto OrfaoMarcos GonzalezRamon Garcia-Sanz
- [8] Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaBLOOD CANCER JOURNAL, 2020, 10 (10)Medina, AlejandroPuig, NoemiFlores-Montero, JuanJimenez, CristinaSarasquete, M. -EugeniaGarcia-Alvarez, MariaPrieto-Conde, IsabelChillon, CarmenAlcoceba, MiguelGutierrez, Norma C.Oriol, AlbertRosinol, LauraBlade, JoanGironella, MercedesHernandez, Miguel T.Gonzalez-Calle, VeronicaCedena, Maria-TeresaPaiva, BrunoSan-Miguel, Jesus F.Lahuerta, Juan-JoseMateos, Maria-VictoriaMartinez-Lopez, JoaquinOrfao, AlbertoGonzalez, MarcosGarcia-Sanz, Ramon
- [9] MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS OF ADULT AND CHILDHOOD ALLBLOOD, 1994, 84 (10) : A300 - A300COYLE, LYAXLEY, JCCOLESINCLAIR, MCHIM, JSCANNELL, PWRIGHT, FMEHTA, ABPRENTICE, HGHOFFBRAND, AVFORONI, L
- [10] Landscape of Next Generation Sequencing (NGS)-based Minimal Residual Disease (MRD) assays for Multiple Myeloma (MM) in ChinaEUROPEAN JOURNAL OF CANCER, 2024, 211 : S80 - S80Shen, S.Dan, D.Yao, Z.